A retrospective study that examined EGFR-mutant NSCLC patients receiving first-line EGFR-TKIs (86% gefitinib and erlotinib, 4.8% afatinib and 9.2% osimertinib) showed that among the group of patients with baseline brain metastases, those harboring uncommon mutations had a significantly shorter intracranial time to progression compared to patients with L858R mutation (23.6 months vs. 68.0 months, p = 0.003) and ex19del (23.6 months vs. NR, p < 0.001). This evidence concerns the gene EGFR and non-small cell lung carcinoma.